https://www.selleckchem.com/pr....oducts/nivolumab.htm
65%). The difference between potential and estimated deaths is higher among women in the age classes between 30 and 74 years.Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an effective and curative treatment for acute myeloid leukemia (AML). We explored the outcome of haploidentical donor (HID) transplantation for intermediate-risk AML and compared to that of matched sibling donor (MSD) transplants. One hundred twenty-seven consecutive patients with intermediate-risk AML in the first complete remission (CR1) who und
Like
Comment
Share
